These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26946426)

  • 1. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
    Wald NJ; Luteijn JM; Morris JK; Taylor D; Oppenheimer P
    Eur J Epidemiol; 2016 Apr; 31(4):415-26. PubMed ID: 26946426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Starting the polypill: the use of a single age cut-off in males and females.
    Wald NJ; Luteijn JM; Morris JK
    J Med Screen; 2017 Mar; 24(1):50-53. PubMed ID: 27072544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
    Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
    BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
    Ferket BS; Hunink MG; Khanji M; Agarwal I; Fleischmann KE; Petersen SE
    Heart; 2017 Apr; 103(7):483-491. PubMed ID: 28077465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
    Lin L; Teng M; Zhao YJ; Khoo AL; Seet RC; Yong QW; Yeo TC; Lim BP
    Cardiovasc Drugs Ther; 2015 Apr; 29(2):187-97. PubMed ID: 25860556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
    Amirsadri M; Hassani A
    Daru; 2015 Dec; 23():56. PubMed ID: 26717884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing screening based on the NHS Health Check and Polypill Prevention Programmes in the primary prevention of heart attacks and strokes.
    Wald NJ; Hingorani AD; Vale SH; Bestwick JP; Morris J
    J Med Screen; 2024 Jun; 31(2):59-65. PubMed ID: 38486473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
    Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
    Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.
    Erickson KF; Japa S; Owens DK; Chertow GM; Garber AM; Goldhaber-Fiebert JD
    J Am Coll Cardiol; 2013 Mar; 61(12):1250-8. PubMed ID: 23500327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of a fixed-dose combination pill for secondary prevention of cardiovascular disease in China, India, Mexico, Nigeria, and South Africa: a modelling study.
    Lin JK; Moran AE; Bibbins-Domingo K; Falase B; Pedroza Tobias A; Mandke CN; Kazi DS
    Lancet Glob Health; 2019 Oct; 7(10):e1346-e1358. PubMed ID: 31477544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost-effectiveness of interventions to improve medication adherence after myocardial infarction.
    Ito K; Shrank WH; Avorn J; Patrick AR; Brennan TA; Antman EM; Choudhry NK
    Health Serv Res; 2012 Dec; 47(6):2097-117. PubMed ID: 22998129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
    Ostovaneh MR; Poustchi H; Hemming K; Marjani H; Pourshams A; Nateghi A; Majed M; Navabakhsh B; Khoshnia M; Jaafari E; Mohammadifard N; Malekzadeh F; Merat S; Sadeghi M; Naemi M; Etemadi A; Thomas GN; Sarrafzadegan N; Cheng KK; Marshall T; Malekzadeh R
    Eur J Prev Cardiol; 2015 Dec; 22(12):1609-17. PubMed ID: 25230980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
    Greving JP; Visseren FL; de Wit GA; Algra A
    BMJ; 2011 Mar; 342():d1672. PubMed ID: 21450800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
    Carey KM; Comee MR; Donovan JL; Kanaan AO
    Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
    Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
    Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
    Chambers M; Hutton J; Gladman J
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.